Press releases
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Jan 3, 2007
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the JP Morgan Health Care Conference, which is being held January 8 - 11 in...
-
Jan 2, 2007Trial highlights the importance of appropriate pacing for patients at risk of sudden cardiac death
Boston Scientific Corporation (NYSE: BSX) today announced that results of the largest implantable cardioverter defibrillator (ICD) study to date,...
-
Dec 15, 2006
Boston Scientific Corporation (NYSE: BSX) today announced that it is voluntarily recalling certain lots of the Mach 1® Guide Catheter in the...
-
Dec 14, 2006Device now cleared for use in both carotid arteries and saphenous vein grafts
Boston Scientific Corporation (NYSE: BSX) today announced it has received clearance from the U.S. Food and Drug Administration (FDA) to market its...
-
Dec 7, 2006
Boston Scientific Corporation (NYSE: BSX) today presented data on its 7,000- patient ARRIVE I and II registries of real-world...
-
Dec 7, 2006
Boston Scientific Corporation (NYSE: BSX) today presented data on its long- term randomized clinical trials to a special U.S....
-
Nov 21, 2006
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Piper Jaffray Health Care Conference, which is being held November 29...
-
Nov 15, 2006
Boston Scientific Corporation (NYSE: BSX) today announced that Brenda Becker will be appointed Senior Vice President of Global Government Affairs....
-
Nov 14, 2006Lower re-intervention rates for the TAXUS Stent in diabetic patients
Boston Scientific Corporation (NYSE: BSX) today welcomed a presentation by Joost Daemen, M.D., and Patrick Serruys, M.D., entitled...
-
Nov 9, 2006
Boston Scientific Corporation (NYSE: BSX) today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's LATITUDE® 2.0...
-
Nov 6, 2006
At a meeting with analysts today, Boston Scientific Corporation (NYSE: BSX) provided its financial outlook for 2007. Sales goals for 2007 range...
-
Nov 6, 2006
Boston Scientific Corporation (NYSE: BSX) today presented a four-year update of its key randomized, controlled clinical trials (TAXUS II, IV, V and...
-
Nov 6, 2006Technology serves as second-generation platform for Company's market-leading TAXUS® paclitaxel-eluting coronary stent system
Boston Scientific Corporation (NYSE: BSX) today announced that it has received approval from the Japanese Ministry of Health, Labor and Welfare...
-
Nov 3, 2006Company to acquire EndoTex
Boston Scientific Corporation (NYSE: BSX) today announced that the U.S. Food and Drug Administration (FDA) has approved the NexStent® Carotid Stent...
-
Nov 3, 2006Innovative Technology Makes Precision™ Spinal Cord Stimulator Accessible to More Patients
Boston Scientific Corporation (NYSE: BSX) today announced that it has received the European CE Mark for its new Artisan™ 2x8 Surgical Lead for use...
-
Nov 2, 2006
Boston Scientific Corporation (NYSE: BSX) today announced that Daniel J. Brennan has been appointed to the position of Vice President Investor...
-
Nov 2, 2006
Boston Scientific Corporation (NYSE: BSX) will simultaneously webcast the analyst meeting it is hosting on Monday, November 6. The meeting is...
-
Nov 1, 2006Thousands of Heart Failure Patients Are Now Eligible for Additional Pacing Feature
Boston Scientific Corporation (NYSE: BSX) today announced the launch of software enabling its Left Ventricular (LV) Offset feature in the Company's...
-
Oct 31, 2006
Boston Scientific Corporation (NYSE: BSX) today announced that Steven L. Zelenkofske, D.O., F.A.C.C., has been appointed Patient Safety Officer and...
-
Oct 25, 2006Positive results also reported for TAXUS Liberte stent direct stenting
Boston Scientific Corporation (NYSE: BSX) today announced 12-month follow-up data from TAXUS ATLAS, the pivotal clinical trial...
-
Oct 25, 2006
Boston Scientific Corporation (NYSE: BSX) today announced positive results from its global TAXUS OLYMPIA registry, supporting the...
-
Oct 23, 2006Results also show statistically significant late stent thrombosis rate for Cypher® stent vs. bare-metal stent
Boston Scientific Corporation (NYSE: BSX) today announced that an independent meta-analysis of more than 3,500 patients from five...
-
Oct 23, 2006Two-year results continue to evaluate long-term safety and efficacy
Boston Scientific (NYSE: BSX) today announced two-year data from its BEACH carotid artery stenting (CAS) clinical trial. The study...
-
Oct 23, 2006Multi-center registry to enroll 10,000 patients over two years
Boston Scientific Corporation (NYSE: BSX) today announced that it intends to provide lead financial support for an extension of the...
-
Oct 22, 2006
Boston Scientific Corporation (NYSE: BSX) today announced one-year results from its TC-WYRE (TAXUS® Express2™ Stent vs. Cypher Stent: What's...